SRM-Ⅳ型前庭功能诊疗系统联合药物治疗耳石症的临床研究  

CLINICAL STUDY OF SRM-N VESTIBULAR FUNCTIONAL DIAGNOSIS AND TREATMENT SYSTEM COMBINED WITH DRUGS FOR BENIGN PAROXYSMAL POSITIONING VERTIGO

作　　者：王丹 张翠芳 秦震新[1] 刘泽民[1] 李斌[1] 左梦露 WANG Dan;ZHANG Cuifang;QIN Zhenxin;LIU Zemin;LI Bin;ZUO Menglu(Department of Neurology,Tangshan People's Hospital,Tangshan 063000,China)

机构地区：[1]河北省唐山市人民医院神经内科,063000

出　　处：《中国煤炭工业医学杂志》2023年第3期303-307,共5页Chinese Journal of Coal Industry Medicine

基　　金：2022年河北医学科学研究课题计划(编号:20221821)。

摘　　要：目的研究SRM-Ⅳ型前庭功能诊疗系统联合甲磺酸倍他司汀、银杏叶提取物片以及苯海拉明治疗耳石症的临床效果。方法92例研究的对象均为该院神经内科2021年1月—2021年12月收治因耳石症引起眩晕的患者,依据治疗方法的不同把耳石症眩晕的患者划分为手法复位的对照组(45例)和联合治疗的观察组(47例)。对照组患者采用手法复位以及其他基础对症治疗,观察组患者采用SRM-Ⅳ型前庭功能诊疗系统诊治并在复位成功后给予甲磺酸倍他司汀、银杏叶提取物片以及苯海拉明联合治疗。二组经治疗后比较复位的对照组和联合治疗的观察组患者不同半规管部位的复位效果情况,采用眩晕障碍量表(dizziness handicapinventory,DHI)比较二组治疗前后眩晕缓解的情况,比较二组治疗1个月后仍然存在头晕症状发生情况以及半年后复发情况;比较二组治疗期间以及治疗1周内出现不适反应的情况。结果治疗后联合治疗的观察组患者不同部位的复位效果明显高于手法复位的对照组;观察组患者眩晕障碍量表评分(DHI)显著低于对照组;治疗后联合治疗的观察组患者1个月后仍存在头晕患者的发生率与手法复位的对照组相比明显降低;治疗后观察组患者半年后的复发率与手法复位的对照组相比明显降低;治疗后联合治疗的观察组患者出现食欲下降、心慌气短、恶心以及口唇干燥等不良反应的例数与手法复位的对照组相比明显降低,以上差异均有统计学意义(均P<0.05)。结论SRM-Ⅳ型前庭功能诊疗系统联合甲磺酸倍他司汀、银杏叶提取物片以及苯海拉明治疗耳石症引起的眩晕以及复位后残余头晕症状的效果明显,对于延缓复发改善复位后残余头晕有更好的临床疗效,可以明显改善其生活质量。Objective To study the clinical effect of SRM-IV vestibular functional diagnosis and treatment system combined with Petastine mesylate,Tablets of Ginkgo biloba leaf extract and diphenhydramine in the treatment of benign paroxysmal positioning vertigo.Methods The ninety-two cases were all patients with vertigo caused by benign paroxysmal positioning vertigo admitted to neurology Department of our hospital from January 2021 to December 2021.The patients with vertigo caused by benign paroxysmal positioning vertigo were divided into control group(forty-five cases)with particle repositioning procedure and study group(forty-seven cases)with combined treatment according to random number table method.The control group was treated with particle repositioning procedure and other basic symptomatic treatment,while the study group was treated with SRM-IV vestibular functional diagnosis and treatment system and was treated with combination of Petamestine mesylate,Tablets of Ginkgo biloba leaf extract and diphenhyramine after successful reduction.The dizziness relief scores of the two groups before and after treatment were compared by dizziness handicap inventory(DHI)in the control group and the combined treatment group.The occurrence of dizziness symptoms still existed one month after treatment and recurrence six months later were compared between the two groups.The two groups were compared for discomfort during treatment and within one week of treatment.Results The reduction effect of different parts in the combined treatment group after treatment was significantly higher than that in the particle repositioning procedure group,and the difference was statistically significant(P<0.05).The score of vertigo disorder scale(DHI)in combined treatment group was significantly lower than that in manual reduction control group,and the difference was statistically significant(P<0.05).The incidence of dizziness in the combined treatment group after one month was significantly lower than that in the particle repositioning procedure group,a

关 键 词：SRM-Ⅳ型前庭功能诊疗系统 手法复位 药物治疗 

分 类 号：R969.4[医药卫生—药理学]